FDA Tentatively Approves Eagle Pharma’s Alimta Copycat

November 1, 2017

The FDA granted tentative approval to Eagle Pharmaceuticals’ version of Eli Lilly’s cancer drug Alimta.

Final approval hinges on the result of a patent battle with Lilly. If Eagle secures that approval, the firm expects to capture between a quarter and a third of the market.

Lilly filed the lawsuit last month, arguing the company infringed on its patents for Alimta, which made Lilly $2.28 billion last year. If the patents are ruled valid, no other company can market a cheaper alternative in the U.S. through May 2022.

View today's stories